IDEMIA Appoints Pierre Barrial as President & Chief Executive Officer of the Group
30.6.2020 09:00:00 EEST | Business Wire | Press release
The supervisory board of IDEMIA has appointed Pierre Barrial as the new President & CEO of the Group, replacing Yann Delabrière who resumes his previous role as Chairman of the Board. Matthew Cole, who has joined the Group, has taken on Pierre Barrial’s previous position as head of the Secure Enterprise Transactions (SET) division.
Over the last 18 months, IDEMIA has restored its growth and cash generation performance after the creation and successful integration of IDEMIA. Yann, who became President & CEO on October 18th 2018, will now be returning to his role as Chairman of the Board with effect from July 1st, 2020, where he will continue to contribute his strategic and governance insights to the company.
Pierre Barrial will succeed Yann as the Group’s President & CEO. He brings over 25 years’ experience with multinational and multicultural tech companies serving both the government and enterprise sectors. Pierre was in charge of SET, having previously managed IDEMIA’s Mobile Operators then Financial Institutions activities, both today part of the SET division. He has partnered with Yann since the beginning of the year as Deputy CEO. Pierre will become IDEMIA’s Group President & CEO starting July 1st, 2020.
Matthew Cole is appointed as head of the SET division, replacing Pierre Barrial. Matthew brings a wealth of experience in this space, having been President of Cubic Transportation Systems, the leading integrator of payment and information solutions and related services for intelligent travel applications in the transportation industry. He will be based in the US and will sit on the Group Executive Committee, as SET division’s CEO.
Yann Delabrière stated: “After a carefully prepared succession plan, we have chosen a world-class executive, Pierre Barrial, to manage the Group. IDEMIA has demonstrated remarkable resilience since the beginning of this year and our business fundamentals are strong and bode well for the future. On behalf of the Board, I wish Pierre all the very best in his new role.”
Pierre Barrial added: “I’m honored and excited to have been chosen as CEO of the Group. IDEMIA has an extremely committed team of 15,000 employees worldwide and together, we’ll continue to serve our clients regardless of the circumstances. I am also proud to head a company whose purpose, since its creation, is to make the world a safer place, whenever and wherever Identity & Security matter in an increasingly digital world. With recent events, this is more true than ever.”
Matthew Cole said: “I am thrilled and proud to join IDEMIA as CEO of the SET division. I plan to work hand in hand with my teams and Group senior management to bring the company’s strategy and growth targets to fruition.”
About Yann Delabrière
Yann Delabrière is a graduate of Ecole Normale Supérieure and Ecole Nationale d’Administration and has a postgraduate degree in mathematics. He began his career at the Committee of Public Accounts (Cour des Comptes) before working for the French External Trade Minister. He then became Chief Financial Officer for the French export credit agency, COFACE, followed by Printemps Group, before becoming Chief Financial Officer for PSA Peugeot Citroën in 1990 and, from 1998, was Chairman and Chief Executive Officer of Banque PSA Finance and sat on the PSA Peugeot Citroën Executive Committee. In 2007 Yann was appointed Chairman and Chief Executive Officer of Faurecia. From June 2017 to February 2018, he chaired the Zodiac Aerospace executive board. From 2004 to May 2018 he was a director of Cap Gemini, from 2012 to 2016 a director of Société Générale and since March 2017 has been a director of Alstom. He has chaired the IDEMIA executive board since October 2018 having previously chaired the IDEMIA supervisory board for a 10-month period.
About Pierre Barrial
Pierre Barrial graduated from Paris School of Business. He comes with over 25 years experience with multinational and multicultural firms and agencies from a broad array of industries including ICT and security, serving both the public and private sectors. After Pierre joined IDEMIA in 2013, he managed the Group’s Latin American operations followed by the Mobile Operators business, the Financial Institutions business and SET. Previously, Pierre worked in various jobs for Bull Group in South Africa, Italy, Poland and Brazil.
About Matthew Cole
Matthew Cole holds an MBA from Oxford Brookes University and is also Chartered Certified Accountant. In 2003 he joined Cubic Corporation, the world leader in smart and contactless payments for transportation. During his time at Cubic Matthew held several senior finance positions before successfully heading up the company’s Asia-Pacific operations followed by global Strategy and Business Development. In 2015, he became President of Cubic Transportation Systems. Before Cubic Corporation, Matthew held several positions with blue-chip multinational firms including Endemol, British Airways, Mitsui, First Choice and Schlumberger.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005779/en/
Contact information
Press:
Hanna Sebbah
idemia@havas.com
+33 (0) 6 63 73 30 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
